개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 276 - 282 (7page)
이용수
초록· 키워드
오류제보하기
Purpose: Valid determination of HER2 status is a prerequisite to establish an adequate treatment strategy for breast cancer patients, regardless of the disease stage. The goal of this study was to examine the feasibility of the newly developed silver-enhanced in situ hybridization (SISH) technique as an alternative to fluorescence in situ hybridization (FISH) for HER2 assay in primary invasive breast cancer. Methods: FISH and SISH for HER2 amplification were performed using tissue microarray. Both methods were used in 257 consecutive primary breast cancers. Results: HER2 amplification was observed in 62 (23.1%) of a total of 257 breast cancers based on SISH. Of the 257 breast cancers measured using both methods, the results of the two methods were consistent in 248 (concordance, 96.5%; kappa=0.903). When we compared HER2 amplification in the primary tumor with the metastatic lymph nodes of the same patients, HER2 amplification was observed in nine cases (14.0%) out of 64 cases in which HER2 was not amplified in the primary tumors. In contrast, HER2 status was completely preserved in metastatic lymph nodes showing HER2 amplification in the primary tumor. Conclusion: These results indicate that SISH can be a feasible alternative to FISH in the clinical setting. In node-positive breast cancer, confirmation of the HER2status of the metastatic lymph nodes ppears to be mandatory, regardless of the HER2 status of the primary tumors.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Geyer CE / 2006 / Lapatinib plus capecitabine for HER2-positive advanced breast cancer / N Engl J Med 355:2733~2743
Wolff AC / 2007 / American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer / J Clin Oncol 25:118~145
Penault-Llorca F / 2009 / Emerging technologies for assessing HER2 amplification / Am J Clin Pathol 132:539~548
Ross JS / 2009 / The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine / Oncologist 14:320~368
Tanner M / 2000 / Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples / Am J Pathol 157:1467~1472
Wolff AC / 2007 / American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer / J Clin Oncol 25:118~145
Penault-Llorca F / 2009 / Emerging technologies for assessing HER2 amplification / Am J Clin Pathol 132:539~548
Ross JS / 2009 / The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine / Oncologist 14:320~368
Tanner M / 2000 / Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples / Am J Pathol 157:1467~1472
이 논문의 저자 정보
최근 본 자료
댓글(0)
0